Protalix Biotherapeutics, Inc. (PLX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1243437,
    "name": "Protalix Biotherapeutics, Inc.",
    "stock_name": "Protalix Biotherapeutics, Inc.",
    "full_name": "Protalix Biotherapeutics, Inc.",
    "name_url": "stocks-analysis/protalix-biotherapeutics-inc",
    "exchange": 215,
    "exchangecode": "ASE",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.75",
    "chg": 0.03,
    "chgp": "1.74%",
    "dir": 1,
    "prev_price": "1.72",
    "mcapval": "125.98",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US74365A3095",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "1.16 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/protalix-biotherapeutics-inc-1243437-215&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Protalix Biotherapeutics Experiences Valuation Adjustment Amidst Competitive Biotechnology Landscape",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protalix-biotherapeutics-changes-valuation-grade-from-attractive-to-fair-amid-price-decline-3707918",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtalixBiother_valuationdot_3707918.png",
        "date": "2025-11-17 15:41:01",
        "description": "Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $1.86. Over the past year, the company has outperformed the S&P 500, achieving a return of 31.91%. Key financial metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%."
      },
      {
        "title": "Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protalix-biotherapeutics-valuation-grade-downgraded-from-very-attractive-to-attractive-3686322",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtalixBiother_valuationdot_3686322.png",
        "date": "2025-11-10 16:13:49",
        "description": "Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $2.19. Over the past year, the company achieved an impressive stock return of 88.79%, outperforming the S&P 500. Key metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%."
      },
      {
        "title": "Protalix Biotherapeutics Stock Forms Golden Cross, Signals Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protalix-biotherapeutics-stock-forms-golden-cross-signals-bullish-breakout-ahead-3667004",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ProtalixBiother_goldencross_3667004.png",
        "date": "2025-11-03 15:15:17",
        "description": "Protalix Biotherapeutics, Inc. recently achieved a Golden Cross, a technical event often seen as a positive indicator. The stock outperformed the S&P 500 today and has shown remarkable growth over the past year. Various technical metrics indicate a bullish sentiment, suggesting optimism about the company's future prospects."
      },
      {
        "title": "Is Protalix Biotherapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protalix-biotherapeutics-inc-overvalued-or-undervalued-3637896",
        "imagepath": "",
        "date": "2025-10-21 12:11:08",
        "description": "As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. with a P/E of 4.74. Additionally, Protalix's EV to EBITDA ratio stands at 15.52, while its peers are demonstrating much lower ratios, suggesting a premium valuation relative to the industry.\n\nIn comparison to its peers, Protalix Biotherapeutics shows a ROCE of 38.92% and a ROE of 8.64%, which are strong indicators of operational efficiency but do not justify its current valuation levels when compared to peers like Puma Biotechnology, which is classified as very attractive. The stock's recent performance against the S&P 500 is not available, but the current valuation metrics sug..."
      },
      {
        "title": "Protalix Biotherapeutics Experiences Revision in Its Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/protalix-biotherapeutics-valuation-grade-downgraded-from-very-attractive-to-attractive-3641121",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/ProtalixBiother_valuationdot_3641121.png",
        "date": "2025-10-20 17:25:29",
        "description": "Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 32 and a price-to-book value of 2.78. The company shows strong operational efficiency, reflected in its high ROCE of 38.92%. Despite year-to-date challenges, it has demonstrated significant resilience over the past year."
      },
      {
        "title": "Is Protalix Biotherapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protalix-biotherapeutics-inc-overvalued-or-undervalued-3634767",
        "imagepath": "",
        "date": "2025-10-20 12:28:26",
        "description": "As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued given its P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. at 4.74, and its EV to EBITDA ratio of 15.52, which also exceeds the industry benchmark. Additionally, the Price to Book Value stands at 2.78, suggesting that the stock may be priced higher than its actual book value.\n\nIn comparison to its peers, Protalix's valuation ratios indicate a less favorable position, with Puma Biotechnology having a much lower P/E and EV to EBITDA, reflecting a more attractive investment opportunity. Furthermore, while Protalix has shown a strong 1-year return of 70.64%, it has underperformed against the S&P 500's 14.08% return over the same period, which reinforces the notion that the stock..."
      },
      {
        "title": "Is Protalix Biotherapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protalix-biotherapeutics-inc-overvalued-or-undervalued-3632308",
        "imagepath": "",
        "date": "2025-10-19 12:05:53",
        "description": "As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 32, significantly higher than its peer Puma Biotechnology, Inc., which has a P/E of 4.74, and a notable EV to EBITDA ratio of 15.52 compared to Puma's 3.15. Additionally, Protalix's Price to Book Value stands at 2.78, suggesting a premium over its book value relative to peers.\n\nIn terms of performance, Protalix has shown strong returns over the past year, with a stock return of 70.64%, outpacing the S&P 500's return of 14.08%. However, the longer-term outlook is less favorable, as the stock has underperformed the S&P 500 over the 5-year and 10-year periods, with returns of -48.90% compared to 91.29% for the index. This mixed performance, combined with high valua..."
      },
      {
        "title": "Is Protalix Biotherapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protalix-biotherapeutics-inc-technically-bullish-or-bearish-3546756",
        "imagepath": "",
        "date": "2025-09-20 19:39:56",
        "description": "As of 9 September 2025, the technical trend for Protalix Biotherapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by weekly MACD and KST indicators, which are both mildly bullish, along with a bullish signal from the Bollinger Bands. However, the daily moving averages remain mildly bearish, indicating some short-term weakness. The Dow Theory also confirms a mildly bullish outlook on both weekly and monthly time frames. \n\nIn terms of performance, the stock has shown a strong 1-year return of 70.64%, significantly outperforming the S&P 500's 17.14% over the same period. However, over the 5-year and 10-year periods, the stock has underperformed relative to the S&P 500...."
      },
      {
        "title": "Is Protalix Biotherapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-protalix-biotherapeutics-inc-overvalued-or-undervalued-3543263",
        "imagepath": "",
        "date": "2025-09-20 18:14:55",
        "description": "As of 28 August 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in market perception. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. at 4.74, and an EV to EBITDA of 15.52 compared to Puma's 3.15. Additionally, the Price to Book Value stands at 2.78, suggesting that the stock may be priced above its intrinsic value relative to its assets.\n\nIn terms of performance, Protalix has shown a strong return of 70.64% over the past year, significantly outperforming the S&P 500's 17.14% return in the same period. However, the long-term outlook appears less favorable, with a 5-year return of -49.04% compared to the S&P 500's impressive 96.61%. Overall, while the recent short-term performance is notable, the valuation me..."
      }
    ],
    "total": 14,
    "sid": "1243437",
    "stock_news_url": "https://www.marketsmojo.com/news/protalix-biotherapeutics-inc-1243437"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Protalix Biotherapeutics Experiences Valuation Adjustment Amidst Competitive Biotechnology Landscape

2025-11-17 15:41:01

Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $1.86. Over the past year, the company has outperformed the S&P 500, achieving a return of 31.91%. Key financial metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%.

Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance

2025-11-10 16:13:49

Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with its stock price at $2.19. Over the past year, the company achieved an impressive stock return of 88.79%, outperforming the S&P 500. Key metrics include a P/E ratio of 32 and a strong return on capital employed of 38.92%.

Protalix Biotherapeutics Stock Forms Golden Cross, Signals Bullish Breakout Ahead

2025-11-03 15:15:17

Protalix Biotherapeutics, Inc. recently achieved a Golden Cross, a technical event often seen as a positive indicator. The stock outperformed the S&P 500 today and has shown remarkable growth over the past year. Various technical metrics indicate a bullish sentiment, suggesting optimism about the company's future prospects.

Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

2025-10-21 12:11:08

As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. with a P/E of 4.74. Additionally, Protalix's EV to EBITDA ratio stands at 15.52, while its peers are demonstrating much lower ratios, suggesting a premium valuation relative to the industry. In comparison to its peers, Protalix Biotherapeutics shows a ROCE of 38.92% and a ROE of 8.64%, which are strong indicators of operational efficiency but do not justify its current valuation levels when compared to peers like Puma Biotechnology, which is classified as very attractive. The stock's recent performance against the S&P 500 is not available, but the current valuation metrics sug...

Protalix Biotherapeutics Experiences Revision in Its Stock Evaluation Amid Market Challenges

2025-10-20 17:25:29

Protalix Biotherapeutics, Inc. has recently adjusted its valuation, with a P/E ratio of 32 and a price-to-book value of 2.78. The company shows strong operational efficiency, reflected in its high ROCE of 38.92%. Despite year-to-date challenges, it has demonstrated significant resilience over the past year.

Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

2025-10-20 12:28:26

As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued given its P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. at 4.74, and its EV to EBITDA ratio of 15.52, which also exceeds the industry benchmark. Additionally, the Price to Book Value stands at 2.78, suggesting that the stock may be priced higher than its actual book value. In comparison to its peers, Protalix's valuation ratios indicate a less favorable position, with Puma Biotechnology having a much lower P/E and EV to EBITDA, reflecting a more attractive investment opportunity. Furthermore, while Protalix has shown a strong 1-year return of 70.64%, it has underperformed against the S&P 500's 14.08% return over the same period, which reinforces the notion that the stock...

Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

2025-10-19 12:05:53

As of 17 October 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in perceived value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 32, significantly higher than its peer Puma Biotechnology, Inc., which has a P/E of 4.74, and a notable EV to EBITDA ratio of 15.52 compared to Puma's 3.15. Additionally, Protalix's Price to Book Value stands at 2.78, suggesting a premium over its book value relative to peers. In terms of performance, Protalix has shown strong returns over the past year, with a stock return of 70.64%, outpacing the S&P 500's return of 14.08%. However, the longer-term outlook is less favorable, as the stock has underperformed the S&P 500 over the 5-year and 10-year periods, with returns of -48.90% compared to 91.29% for the index. This mixed performance, combined with high valua...

Is Protalix Biotherapeutics, Inc. technically bullish or bearish?

2025-09-20 19:39:56

As of 9 September 2025, the technical trend for Protalix Biotherapeutics, Inc. has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by weekly MACD and KST indicators, which are both mildly bullish, along with a bullish signal from the Bollinger Bands. However, the daily moving averages remain mildly bearish, indicating some short-term weakness. The Dow Theory also confirms a mildly bullish outlook on both weekly and monthly time frames. In terms of performance, the stock has shown a strong 1-year return of 70.64%, significantly outperforming the S&P 500's 17.14% over the same period. However, over the 5-year and 10-year periods, the stock has underperformed relative to the S&P 500....

Is Protalix Biotherapeutics, Inc. overvalued or undervalued?

2025-09-20 18:14:55

As of 28 August 2025, the valuation grade for Protalix Biotherapeutics, Inc. has moved from very attractive to attractive, indicating a shift in market perception. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 32, which is significantly higher than its peer Puma Biotechnology, Inc. at 4.74, and an EV to EBITDA of 15.52 compared to Puma's 3.15. Additionally, the Price to Book Value stands at 2.78, suggesting that the stock may be priced above its intrinsic value relative to its assets. In terms of performance, Protalix has shown a strong return of 70.64% over the past year, significantly outperforming the S&P 500's 17.14% return in the same period. However, the long-term outlook appears less favorable, with a 5-year return of -49.04% compared to the S&P 500's impressive 96.61%. Overall, while the recent short-term performance is notable, the valuation me...

View All News